A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor
作者： Kyeong Lee , Hwan Mook Kim
DOI: 10.1007/S12272-011-1021-3
关键词:
摘要: Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and key regulator of number genes important in cancer biology. Over-expression HIF-1α human tumors associated with poor prognosis therapeutic outcomes has been suggested as novel target for therapy. This article provides review PX-478 the first inhibitor clinical stage treatment solid tumors.
springer.com
sci-hub.se 参考文章(12)
Andrew L. Kung, Stream Wang, Jeffery M. Klco, William G. Kaelin, David M. Livingston, Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Medicine. ,vol. 6, pp. 1335- 1340 ,(2000) , 10.1038/82146
Gillian Paine-Murrieta, Sarah Welsh, Lynn Kirkpatrick, Ryan Williams, Garth Powis, Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α Molecular Cancer Therapeutics. ,vol. 3, pp. 233- 244 ,(2004)
Gerald W. Hart, John B. Lowe, Neeraja Sathyamoorthy, Glycobiology and Cancer: Meeting Summary and Future Directions Cancer Biology & Therapy. ,vol. 3, pp. 233- 237 ,(2004) , 10.4161/CBT.3.2.775
Vladimir E Belozerov, Erwin G Van Meir, None, Hypoxia inducible factor-1: a novel target for cancer therapy. Anti-Cancer Drugs. ,vol. 16, pp. 901- 909 ,(2005) , 10.1097/01.CAD.0000180116.85912.69
Barbara Onnis, Annamaria Rapisarda, Giovanni Melillo, Development of HIF-1 inhibitors for cancer therapy Journal of Cellular and Molecular Medicine. ,vol. 13, pp. 2780- 2786 ,(2009) , 10.1111/J.1582-4934.2009.00876.X
Gordon R Macpherson, William Figg, II, Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biology & Therapy. ,vol. 3, pp. 503- 504 ,(2004) , 10.4161/CBT.3.6.961
Ji-Won Lee, Seong-Hui Bae, Joo-Won Jeong, Se-Hee Kim, Kyu-Won Kim, Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Experimental and Molecular Medicine. ,vol. 36, pp. 1- 12 ,(2004) , 10.1038/EMM.2004.1
David L. Schwartz, James A. Bankson, Robert Lemos, Stephen Y. Lai, Arun K. Thittai, Yi He, Galen Hostetter, Michael J. Demeure, Daniel D. Von Hoff, Garth Powis, Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer Molecular Cancer Therapeutics. ,vol. 9, pp. 2057- 2067 ,(2010) , 10.1158/1535-7163.MCT-09-0768
Mei Y Koh, Taly Spivak-Kroizman, Sara Venturini, Sarah Welsh, Ryan R Williams, D Lynn Kirkpatrick, Garth Powis, None, Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α Molecular Cancer Therapeutics. ,vol. 7, pp. 90- 100 ,(2008) , 10.1158/1535-7163.MCT-07-0463
Uday Mukhopadhay, Zhenghong Peng, William Bornmann, Juri Gelovani, David L. Schwartz, Garth Powis, Arun Thitai-Kumar, Yi He, James Bankson, Ryan Williams, Robert Lemos, Junghwan Oh, Andrei Volgin, Suren Soghomonyan, Ryuichi Nishii, Mian Alauddin, The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Molecular Cancer Therapeutics. ,vol. 8, pp. 947- 958 ,(2009) , 10.1158/1535-7163.MCT-08-0981